

## Claims

1. A therapeutic agent for Alzheimer's disease, Parkinson's disease, cerebral infarction, head injuries, cerebral hemorrhage, spinal injuries, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, diabetic or drug-induced peripheral nerve disorders or retinal nerve disorders, which comprises a PPAR $\delta$  agonist as an active ingredient.

2. A therapeutic method for Alzheimer's disease, Parkinson's disease, cerebral infarction, head injuries, cerebral hemorrhage, spinal injuries, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, diabetic or drug-induced peripheral nerve disorders or retinal nerve disorders, which comprises administering a pharmaceutical agent comprising a PPAR $\delta$  agonist as an active ingredient.

3. A therapeutic agent for cerebral infarction, which comprises a PPAR $\delta$  agonist as an active ingredient.

4. A therapeutic agent for Parkinson's disease, which comprises a PPAR $\delta$  agonist as an active ingredient.

5. A therapeutic method for cerebral infarction, which comprises administering a pharmaceutical agent comprising a PPAR $\delta$  agonist as an active ingredient.

5 6. A therapeutic method for Parkinson's disease, which comprises administering a pharmaceutical agent comprising a PPAR $\delta$  agonist as an active ingredient.

10 7. The therapeutic agent according to claim 1, 3 or 4, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

15 8. The therapeutic method according to claim 2, 5 or 6, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

20 9. The therapeutic agent according to claim 1, 3 or 4, wherein the PPAR $\delta$  agonist is L-165041 or GW501516.

10. The therapeutic method according to claim 2, 5 or 6, wherein the PPAR $\delta$  agonist is L-165041 or GW501516.

25 11. Use of a PPAR $\delta$  agonist for the manufacture of a therapeutic agent for Alzheimer's disease, Parkinson's

disease, cerebral infarction, head injuries, cerebral hemorrhage, spinal injuries, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, diabetic or drug-induced peripheral nerve disorders or retinal nerve disorders.

12. Use of a PPAR $\delta$  agonist for the manufacture of a therapeutic agent for cerebral infarction.

13. Use of a PPAR $\delta$  agonist for the manufacture of a therapeutic agent for Parkinson's disease.

14. The use according to any of claims 11 through 13, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

15. The use according to any of claims 11 through 13, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

16. An agent of suppressing the death of central nerve cell, which comprises a PPAR $\delta$  agonist as an active ingredient.

17. The agent of suppressing the death of central nerve cell according to claim 16, wherein the PPAR $\delta$  agonist is L-165041 or GWW501516.